CytRx Company Profile (NASDAQ:CYTR)

About CytRx (NASDAQ:CYTR)

CytRx logoCytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYTR
  • CUSIP: N/A
  • Web: www.cytrx.com
Capitalization:
  • Market Cap: $111 million
  • Outstanding Shares: 152,054,000
Average Prices:
  • 50 Day Moving Avg: $0.52
  • 200 Day Moving Avg: $0.46
  • 52 Week Range: $0.36 - $3.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.78
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $200,000.00
  • Price / Sales: 555.00
  • Book Value: $0.12 per share
  • Price / Book: 6.08
Profitability:
  • EBIDTA: ($49,290,000.00)
  • Return on Equity: -213.82%
  • Return on Assets: -99.93%
Debt:
  • Debt-to-Equity Ratio: 0.86%
  • Current Ratio: 3.06%
  • Quick Ratio: 3.06%
Misc:
  • Average Volume: 4.84 million shs.
  • Beta: 1.34
  • Short Ratio: 7.79
 

Frequently Asked Questions for CytRx (NASDAQ:CYTR)

What is CytRx's stock symbol?

CytRx trades on the NASDAQ under the ticker symbol "CYTR."

How were CytRx's earnings last quarter?

CytRx Co. (NASDAQ:CYTR) released its earnings results on Wednesday, May, 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. View CytRx's Earnings History.

Where is CytRx's stock going? Where will CytRx's stock price be in 2017?

4 brokers have issued twelve-month price objectives for CytRx's stock. Their predictions range from $0.75 to $4.00. On average, they expect CytRx's stock price to reach $2.13 in the next twelve months. View Analyst Ratings for CytRx.

Are investors shorting CytRx?

CytRx saw a decrease in short interest in May. As of May 15th, there was short interest totalling 10,653,099 shares, a decrease of 51.6% from the April 28th total of 22,015,582 shares. Based on an average daily trading volume, of 3,397,304 shares, the short-interest ratio is presently 3.1 days. Approximately 9.5% of the shares of the company are sold short.

Who are some of CytRx's key competitors?

Who owns CytRx stock?

CytRx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (8.07%), Vanguard Group Inc. (2.67%), Sabby Management LLC (0.65%), Geode Capital Management LLC (0.63%), Renaissance Technologies LLC (0.51%) and Morgan Stanley (0.20%). View Institutional Ownership Trends for CytRx.

Who sold CytRx stock? Who is selling CytRx stock?

CytRx's stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC and Morgan Stanley. View Insider Buying and Selling for CytRx.

Who bought CytRx stock? Who is buying CytRx stock?

CytRx's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., SG Americas Securities LLC and Geode Capital Management LLC. View Insider Buying and Selling for CytRx.

How do I buy CytRx stock?

Shares of CytRx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CytRx stock cost?

One share of CytRx stock can currently be purchased for approximately $0.73.

Analyst Ratings

Consensus Ratings for CytRx (NASDAQ:CYTR) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $2.13 (191.10% upside)

Analysts' Ratings History for CytRx (NASDAQ:CYTR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017HC WainwrightReiterated RatingBuy$4.00HighView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
11/14/2016FBR & CoSet Price TargetBuy$3.00N/AView Rating Details
7/15/2016Jefferies Group LLCReiterated RatingHold$2.50 -> $0.75N/AView Rating Details
7/12/2016S&P Equity ResearchLower Price Target$1.04 -> $0.75N/AView Rating Details
11/6/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for CytRx (NASDAQ:CYTR)
Earnings by Quarter for CytRx (NASDAQ:CYTR)
Earnings History by Quarter for CytRx (NASDAQ:CYTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.10)ViewN/AView Earnings Details
7/29/2016Q2($0.19)($0.27)$0.10 millionViewN/AView Earnings Details
5/11/2016Q116($0.26)($0.19)ViewN/AView Earnings Details
11/3/2015Q315($0.24)($0.17)ViewN/AView Earnings Details
8/3/2015Q215($0.27)($0.25)ViewN/AView Earnings Details
5/1/2015Q115($0.21)($0.28)ViewN/AView Earnings Details
3/10/2015Q4 2014($0.27)($0.24)$0.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.25)($0.10)ViewN/AView Earnings Details
8/6/2014Q214($0.20)($0.28)ViewN/AView Earnings Details
3/5/2014($0.17)($0.25)$0.10 millionViewN/AView Earnings Details
10/29/2013Q313($0.22)($0.33)$0.20 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.19)($0.11)ViewN/AView Earnings Details
5/9/2013Q113($0.15)($0.23)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.20)($0.21)ViewN/AView Earnings Details
11/9/2012Q312$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytRx (NASDAQ:CYTR)
Current Year EPS Consensus Estimate: $-0.50 EPS
Next Year EPS Consensus Estimate: $-0.41 EPS

Dividends

Dividend History for CytRx (NASDAQ:CYTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CytRx (NASDAQ:CYTR)
Insider Ownership Percentage: 12.40%
Institutional Ownership Percentage: 20.19%
Insider Trades by Quarter for CytRx (NASDAQ:CYTR)
Institutional Ownership by Quarter for CytRx (NASDAQ:CYTR)
Insider Trades by Quarter for CytRx (NASDAQ:CYTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/3/2013Scott Bradford Pattersonmajor shareholderBuy284,979$2.44$695,348.76View SEC Filing  
11/7/2013Scott Bradford PattersonMajor ShareholderBuy50,000$2.06$103,000.00View SEC Filing  
4/1/2013Scott Bradford PattersonMajor ShareholderBuy4,083$2.70$11,024.10View SEC Filing  
3/20/2013Scott Bradford PattersonMajor ShareholderBuy3,980$2.61$10,387.80View SEC Filing  
3/13/2013Scott Bradford PattersonMajor ShareholderBuy55,360$2.67$147,811.20View SEC Filing  
10/22/2012Scott Bradford PattersonMajor ShareholderBuy180,000$2.51$451,800.00View SEC Filing  
10/18/2012Scott Bradford PattersonMajor ShareholderBuy1,200,000$2.50$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CytRx (NASDAQ:CYTR)
Latest Headlines for CytRx (NASDAQ:CYTR)
Source:
DateHeadline
benzinga.com logoMost Notable Abstracts Released Ahead Of ASCO 2017 | Benzinga - Benzinga
www.benzinga.com - May 19 at 4:29 PM
finance.yahoo.com logoThe Most Notable Abstracts Released Ahead Of ASCO 2017
finance.yahoo.com - May 19 at 4:29 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx
finance.yahoo.com - May 19 at 8:22 AM
streetinsider.com logoB. Riley Financial (RILY) Announces $67M Acquisition of Wunderlich Securities
www.streetinsider.com - May 18 at 10:45 AM
finance.yahoo.com logoCytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 9:45 PM
americanbankingnews.com logoCytRx Co. (CYTR) Posts Earnings Results
www.americanbankingnews.com - May 11 at 6:54 PM
americanbankingnews.com logoCytRx Co. (CYTR) Sees Large Growth in Short Interest
www.americanbankingnews.com - May 11 at 7:20 AM
finance.yahoo.com logoCytRx Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 4:50 PM
finance.yahoo.com logoCytRx reports 1Q loss
finance.yahoo.com - May 10 at 4:50 PM
ft.com logoFake news infiltrates financial markets
www.ft.com - May 5 at 2:51 AM
streetinsider.com logoCytRx (CYTR) Announces Offering of Common Stock
www.streetinsider.com - April 29 at 10:18 PM
prnewswire.com logoCytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock - PR Newswire (press release)
www.prnewswire.com - April 29 at 5:17 PM
streetinsider.com logoCytRx (CYTR) Prices 30M Common Stock Offering at $0.50/Share
www.streetinsider.com - April 29 at 10:28 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Starbucks, Time Inc ... - Nasdaq
www.nasdaq.com - April 28 at 10:42 PM
prnewswire.com logoCytRx Corporation Announces Proposed Public Offering of Common Stock - PR Newswire (press release)
www.prnewswire.com - April 28 at 3:13 AM
americanbankingnews.com logoCytRx (CYTR) Receiving Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - April 27 at 10:48 PM
finance.yahoo.com logoCytRx Corporation Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 27 at 10:12 PM
finance.yahoo.com logoPenny Stocks to Watch for May 2017
finance.yahoo.com - April 27 at 5:10 PM
americanbankingnews.com logoCytRx Co. (CYTR) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - April 26 at 9:02 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Likely to Affect CytRx (CYTR) Share Price
www.americanbankingnews.com - April 24 at 6:34 PM
finance.yahoo.com logoCytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)
finance.yahoo.com - April 21 at 12:23 PM
finance.yahoo.com logoCytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
finance.yahoo.com - April 20 at 9:48 PM
americanbankingnews.com logoCytRx (CYTR) Receiving Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 20 at 8:59 PM
finance.yahoo.com logoBlog Coverage CytRx Announces FDA's Approval for New Drug Application
finance.yahoo.com - April 20 at 4:47 PM
finance.yahoo.com logoETFs with exposure to CytRx Corp. : April 20, 2017
finance.yahoo.com - April 20 at 4:47 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, IBM, Textron ... - Nasdaq
www.nasdaq.com - April 19 at 9:39 PM
streetinsider.com logoIBM sends S&P 500, Dow lower; Nasdaq advances
www.streetinsider.com - April 19 at 4:37 PM
streetinsider.com logoIntegris Software Launches and Unveils Data Privacy Platform for Global Enterprises
www.streetinsider.com - April 19 at 12:34 PM
finance.yahoo.com logoCytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
finance.yahoo.com - April 19 at 12:34 PM
thestreet.com logoFor These Small-Cap Biotech CEOs, Stock Promotion, Not Drug ... - TheStreet.com
www.thestreet.com - April 13 at 4:39 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Very Unlikely to Effect CytRx (CYTR) Share Price
www.americanbankingnews.com - April 13 at 3:49 PM
finance.yahoo.com logoETFs with exposure to CytRx Corp. : April 7, 2017
finance.yahoo.com - April 7 at 4:37 PM
americanbankingnews.com logoCytRx Co. (CYTR) Stock Rating Reaffirmed by Aegis
www.americanbankingnews.com - March 23 at 8:53 AM
finance.yahoo.com logoCYTRX CORP Financials
finance.yahoo.com - March 21 at 4:55 PM
finance.yahoo.com logoCytRx Reports 2016 Financial Results
finance.yahoo.com - March 15 at 5:03 PM
biz.yahoo.com logoCYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 15 at 5:03 PM
finance.yahoo.com logoCytRx to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 7 at 12:05 PM
biz.yahoo.com logoCYTRX CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
biz.yahoo.com - February 24 at 10:10 PM
finance.yahoo.com logoCytRx to Present at the 19th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 4:41 PM
biz.yahoo.com logoCYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 30 at 9:52 AM
reuters.com logoBRIEF-Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin
www.reuters.com - January 4 at 5:42 PM
finance.yahoo.com logoCytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment …
finance.yahoo.com - January 4 at 5:42 PM
nasdaq.com logoIs the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock? - Nasdaq
www.nasdaq.com - December 30 at 10:02 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock?
finance.yahoo.com - December 30 at 5:01 PM

Social

Chart

CytRx (CYTR) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff